Injecting CpG-ODN to enhance immune response against advanced solid tumors
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors
PHASE1 · Second Affiliated Hospital of Guangzhou Medical University · NCT04952272
This study is testing whether injecting a special substance into tumors can help the immune system fight advanced solid tumors better, either on its own or with another treatment that targets specific cancer cells.
Quick facts
| Phase | PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University (other) |
| Drugs / interventions | CAR-T |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT04952272 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and clinical effects of injecting CpG-ODN directly into tumors, combined with techniques like microwave ablation or drug-eluting beads to release tumor-specific antigens. The approach aims to stimulate the immune system to target and kill cancer cells more effectively. Participants will receive either the CpG-ODN injection alone or in combination with CAR-T cells that target the OX40 receptor. The study will assess both the side effects and the therapeutic efficacy of these combined treatments.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 80 with advanced malignant solid tumors and a life expectancy of more than three months.
Not a fit: Patients with benign tumors, those with a life expectancy of less than three months, or those with serious medical comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the immune response against advanced solid tumors, potentially improving patient outcomes.
How similar studies have performed: While this approach is innovative, similar studies using immune modulation techniques have shown promise in treating various cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Solid advanced malignant tumors * Age between18 and 80 years * Life expectancy is greater than three months Exclusion Criteria: * Benign tumor * Life expectancy is less than three months * Serious medical comorbidity * Others
Where this trial is running
Guangzhou, Guangdong
- The Second Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (RECRUITING)
Study contacts
- Principal investigator: Zhenfeng Zhang, MD, PhD — Second Affiliated Hospital of Guangzhou Medical University
- Study coordinator: Zhenfeng Zhang, MD, PhD
- Email: zhangzhf@gzhmu.edu.cn
- Phone: +862039195966
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer, Hepatocellular Carcinoma, Solid Tumor